Syneos Health is in the medical diagnostics and research industry and healthcare sector. The company CEO is Alistair Macdonald. Syneos Health Inc is a Contract Research Organization providing clinical development services for biopharmaceutical and medical device industries. It operates in North America, Europe, Middle East and Africa, Asia-Pacific and Latin America.
Previous Intraday Trading Performance:
The SYNH stock showed a previous change of 0.28% with an open at 42.98 and a close of 43.02. It reached an intraday high of 43.72 and a low of 42.53.
The stock has a market cap of $4.5b with 103.8m shares outstanding, of which the float is 102.8m shares. Trading volume reached 494,348 shares compared to its average volume of 663,827 shares. Based on the current average volume and close price, the trading liquidity is good.
Historical Trading Performance:
Over the last five trading days, Syneos Health shares returned -6.42% and in the past 30 trading days it returned -16.42%. Over three months, it changed -18.62%. In one year it has changed 3.29% and within that year its 52-week high was 56.34 and its 52-week low was 36.27. SYNH stock is 18.63% above its 52 Week Low.
Our calculations show a 200 day moving average of 47.93 and a 50 day moving average of 47.44. Currently SYNH stock is trading -10.24% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.
The last annual fiscal EPS for the company was reported at 0.23 that ended on 31st of December 2018, which according to the previous close, that is a PE of 187.04. Based on 6 analyst estimates, the consensus EPS for the next quarter is 0.51. The TTM EPS is 2.62, which comes to a TTM PE of 16.42.
Base on our calculations, the intrinsic value per share is 77.38, which means it is possibly undervalued and has a margin of safety of 44.40%
Indicators to Watch:
Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.
The current calculated beta is 1.40
SeekingAlpha: Syneos Health misses by $0.02, beats on revenue
Based on last reported financials, the company’s return on equity is 0.69%, return on assets is 0.27%, profit margin is 0.40%, price-to-sales is 1.00 and price-to-book is 1.57.
All scores are out of six:
3 :Valuation Score
0 :Past Performance Score
2 :Financial Strength Score
3 :Future Growth Score
0 :Dividend Score
2 :Overall Score